Psilocybin mushroom (Psilocybe spp.) therapy is being rolled out across Canada through the CAN-PACT program, which will run a multi-site randomized trial using a 25 mg high-dose psilocybin session in people with advanced cancer (stage III–IV). Prior trials show single-dose psilocybin reduced depression and anxiety with large effect sizes and sustained drops in demoralization and suicidal ideation for up to 4.5 years. CAN-PACT will standardize clinician training, safety protocols, and Health Canada regulatory pathways to enable national clinical access if efficacy and safety are confirmed.